Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
The conversation discusses using RU58841 for hair loss, with OP applying a 5% premixed solution from Receptorchem daily. Users express skepticism about the rapid results and inquire about other treatments and costs.
The conversation discusses the effectiveness of RU58841 and pyrilutamide for hair loss treatment. It seeks personal success or failure stories and scientific data on these treatments.
Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.
The conversation is about finding a source for RU58841 as a substitute for finasteride for hair loss treatment. Suggestions include Amazon and Anageninc.com.
Finasteride increased the user's estrogen levels by 51%, causing concerns about gynecomastia and sleep issues. Despite potential side effects, the user prefers continuing finasteride to prevent hair loss, considering it essential for self-esteem.
RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.
The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.
The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.
RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.
RU58841 and Minoxidil can cause heart-related side effects like chest pain and heart racing. Pyrilutamide is suggested as a safer alternative, though it's new and costly.
The conversation is about finding reputable clinics in Belgium, the Netherlands, France, or Germany for PRP with double centrifugation or exosome therapy for hair loss. The user seeks recommendations based on personal experiences or good reviews.
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.
The conversation is about finding providers for Dutasteride Mesotherapy in the US, which is more common in Europe. The user is asking if any mesotherapy/PRP clinic could offer it if they provide the Dutasteride.
The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.
The conversation discusses using a combination of redensyl, capixyl, and procapil (RCP) for hair loss, with some users also mentioning minoxidil and finasteride. Users shared mixed experiences, with some suggesting "RevivHair Max Hair Stimulating Serum" for better results, while others reported no noticeable effects from using products like The Ordinary Multi-Peptide Serum.
Applying Epidermal Growth Factor (EGF) topically may improve skin and potentially promote scalp health and hair growth, especially after microneedling. The user shares their positive experience with EGF and provides a product link.
Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
Regenera Activa and exosome therapy are discussed for hair loss treatment, focusing on their effectiveness for regrowth, thickening, or reducing shedding. Users are seeking experiences and results from these treatments.
Pyrilutamide is officially available for purchase, and users suggest Fluridil as an alternative topical anti-androgen. Some users report positive results with pyrilutamide from Koshine.
RU58841 is absorbed systemically in humans, contradicting claims it stays local, but no harm is proven. Alternatives like CB-03-01 or KX-826, especially with finasteride, are suggested for safety.
RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Topical 2-deoxy-D-ribose (2dDR) regrows hair in mice almost as well as 2% Minoxidil. However, 2dDR may contribute to oxidative stress and hair loss due to the formation of advanced glycation end products (AGEs).
The conversation discusses obtaining RU58841 in Germany without international shipping, with users sharing experiences and advice. The original poster has been using RU58841 for three years and is seeking local sources to avoid customs issues.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.